LEADER 00000nam a2200481 i 4500 
001    978-3-319-10527-7 
003    DE-He213 
005    20150724100116.0 
006    m     o  d         
007    cr nn 008maaau 
008    141110s2015    gw      s         0 eng d 
020    9783319105277 (electronic bk.) 
020    9783319105260 (paper) 
024 7  10.1007/978-3-319-10527-7|2doi 
040    GP|cGP|erda|dAS 
041 0  eng 
050  4 RC159.A5 
082 04 616.9362061|223 
100 1  Kiang, Tony K.L.,|eauthor 
245 10 Clinical pharmacokinetic and pharmacodynamic drug 
       interactions associated with antimalarials /|cby Tony K.L.
       Kiang, Kyle John Wilby, Mary H.H. Ensom 
264  1 Cham :|bSpringer International Publishing :|bImprint: Adis,
300    1 online resource (vii, 146 pages) :|billustrations, 
       digital ;|c24 cm 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file|bPDF|2rda 
505 0  Introduction -- Pharmacology of Recommended Antimalarial 
       Agents -- Drug Interaction Potential of Antimalarial Drugs
       Based on Known Metabolic Properties of Antimalarials -- 
       Pharmacokinetic Drug Interactions Affecting Antimalarials 
       -- Effects of Antimalarials on the Pharmacokinetics of Co-
       Administered Drugs -- Effects of Antimalarials on the 
       Pharmacokinetics of Co-Administered Antimalarials -- 
       Pharmacodynamic Interactions: Clinical Evidence for 
       Combination Therapy, In Vitro Interactions, and In Vivo 
       Interactions -- Limitations, Future Directions, and 
520    This comprehensive review provides a systematic, unbiased 
       analysis, critique and summary of the available literature
       and generates novel clinical decision-making algorithms 
       which can aid clinicians and scientists in practice 
       management and research development. Potential mechanisms 
       for the identified drug interactions are deduced from 
       available preclinical and in vitro data which are 
       interpreted in the context of the in vivo findings. 
       Current limitations and gaps in the literature are 
       summarized, and potential future research directions / 
       experimentations are also suggested. In addition to the 
       main objective to review the available clinical 
       pharmacokinetic and pharmacodynamic drug interactions 
       associated with WHO-recommended antimalarial drugs on the 
       market today (i.e. chloroquine, amodiaquine, sulfadoxine, 
       pyrimethamine, mefloquine, artemisinin, artemether, 
       artesunate, dihydroartemisinin, artemotil, lumefantrine, 
       primaquine, atovaquone, proguanil, piperaquine and 
       quinine), this book also provides succinct chapter 
       summaries on the epidemiology of malaria infection, 
       diagnosis and therapeutics, in vivo pharmacology and 
       chemistry, preclinical pharmacology, in vitro 
       pharmacodynamics, in vitro reaction phenotyping, and in 
       vitro drug-drug interaction data associated with the 
       identified antimalarial drugs 
590    Springer 
650  0 Antimalarials|xPharmacokinetics 
650  0 Antimalarials|xReceptors|xEffect of drugs on 
650 14 Medicine & Public Health 
650 24 Tropical Medicine 
650 24 Health Promotion and Disease Prevention 
650 24 Drug Safety and Pharmacovigilance 
700 1  Wilby, Kyle John,|eauthor 
700 1  Ensom, Mary H.H.,|eauthor 
710 2  SpringerLink (Online service) 
773 0  |tSpringer eBooks 
856 40 |uhttp://dx.doi.org/10.1007/978-3-319-10527-7